Pentadecapeptide BPC-157 Arginate (BPC-ARG)

Arginine salt form of BPC-157 with enhanced stability and potentially improved bioavailability compared to acetate form.

Key Data

Research Status

Preclinical

Half-Life

4-6 hours

Administration

Subcutaneous injection

Typical Dosage

250-500 mcg

Mechanism of Action

Same as BPC-157 with arginine counter-ion for improved stability in aqueous solutions.

Reported Benefits

• Enhanced stability
• Same healing properties as BPC-157
• Better solubility

All information is presented for Research Use Only (RUO). Not medical advice.